62 related articles for article (PubMed ID: 24406213)
1. Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells.
Reguera-Nuñez E; Roca C; Hardy E; de la Fuente M; Csaba N; Garcia-Fuentes M
Biomaterials; 2014 Mar; 35(9):2859-67. PubMed ID: 24406213
[TBL] [Abstract][Full Text] [Related]
2. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma.
González-Gómez P; Crecente-Campo J; Zahonero C; de la Fuente M; Hernández-Laín A; Mira H; Sánchez-Gómez P; Garcia-Fuentes M
Oncotarget; 2015 May; 6(13):10950-63. PubMed ID: 25860932
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold.
Jeon O; Song SJ; Kang SW; Putnam AJ; Kim BS
Biomaterials; 2007 Jun; 28(17):2763-71. PubMed ID: 17350678
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells.
Chirasani SR; Sternjak A; Wend P; Momma S; Campos B; Herrmann IM; Graf D; Mitsiadis T; Herold-Mende C; Besser D; Synowitz M; Kettenmann H; Glass R
Brain; 2010 Jul; 133(Pt 7):1961-72. PubMed ID: 20513660
[TBL] [Abstract][Full Text] [Related]
5. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
6. Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2.
Fu YC; Nie H; Ho ML; Wang CK; Wang CH
Biotechnol Bioeng; 2008 Mar; 99(4):996-1006. PubMed ID: 17879301
[TBL] [Abstract][Full Text] [Related]
7. Sequential BMP-2/BMP-7 delivery from polyester nanocapsules.
Yilgor P; Hasirci N; Hasirci V
J Biomed Mater Res A; 2010 May; 93(2):528-36. PubMed ID: 19585564
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme.
Ong BY; Ranganath SH; Lee LY; Lu F; Lee HS; Sahinidis NV; Wang CH
Biomaterials; 2009 Jun; 30(18):3189-96. PubMed ID: 19285718
[TBL] [Abstract][Full Text] [Related]
9. Continuous delivery of endogenous inhibitors from poly(lactic-co-glycolic acid) polymeric microspheres inhibits glioma tumor growth.
Benny O; Duvshani-Eshet M; Cargioli T; Bello L; Bikfalvi A; Carroll RS; Machluf M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):768-76. PubMed ID: 15701867
[TBL] [Abstract][Full Text] [Related]
10. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering.
Yilgor P; Tuzlakoglu K; Reis RL; Hasirci N; Hasirci V
Biomaterials; 2009 Jul; 30(21):3551-9. PubMed ID: 19361857
[TBL] [Abstract][Full Text] [Related]
12. Wnt antagonist, secreted frizzled-related protein 4 (sFRP4), increases chemotherapeutic response of glioma stem-like cells.
Warrier S; Balu SK; Kumar AP; Millward M; Dharmarajan A
Oncol Res; 2013; 21(2):93-102. PubMed ID: 24406045
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices.
Hickey T; Kreutzer D; Burgess DJ; Moussy F
J Biomed Mater Res; 2002 Aug; 61(2):180-7. PubMed ID: 12007197
[TBL] [Abstract][Full Text] [Related]
14. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases.
Lavi G; Voronov E; Dinarello CA; Apte RN; Cohen S
J Control Release; 2007 Nov; 123(2):123-30. PubMed ID: 17900737
[TBL] [Abstract][Full Text] [Related]
15. Effects of low concentration BMP-7 on human osteoarthritic chondrocytes: comparison of different applications.
Gavenis K; Heussen N; Schmidt-Rohlfing B
J Biomater Appl; 2012 Mar; 26(7):845-59. PubMed ID: 21123280
[TBL] [Abstract][Full Text] [Related]
16. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
Liu YS; Hsu HC; Tseng KC; Chen HC; Chen SJ
Biomed Pharmacother; 2013 Oct; 67(8):791-9. PubMed ID: 24138824
[TBL] [Abstract][Full Text] [Related]
17. Controlled release of bone morphogenetic protein (BMP)-2 from nanocomplex incorporated on hydroxyapatite-formed titanium surface.
Bae SE; Choi J; Joung YK; Park K; Han DK
J Control Release; 2012 Jun; 160(3):676-84. PubMed ID: 22543042
[TBL] [Abstract][Full Text] [Related]
18. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model.
Benny O; Kim SK; Gvili K; Radzishevsky IS; Mor A; Verduzco L; Menon LG; Black PM; Machluf M; Carroll RS
FASEB J; 2008 Feb; 22(2):488-99. PubMed ID: 17873103
[TBL] [Abstract][Full Text] [Related]
19. Controlled release of bioactive doxorubicin from microspheres embedded within gelatin scaffolds.
Defail AJ; Edington HD; Matthews S; Lee WC; Marra KG
J Biomed Mater Res A; 2006 Dec; 79(4):954-62. PubMed ID: 16941588
[TBL] [Abstract][Full Text] [Related]
20. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
